Insider Trading activities of Neurocrine Biosciences Inc insiders. , Part 2

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurocrine Biosciences Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Neurocrine Biosciences Inc since 2005. The reporting company's ticker symbol is NBIX. The reporting company's CIK number is 914475.
The total value of stock buying since 2005 is $10,350,601.
The total value of stock sales since 2005 is $110,891,474.
The total value of stock option exercises since 2005 is $12,381,183.


 1   2   3 

Table 2. Detailed insider stock purchases, sales, and option exercises of Neurocrine Biosciences Inc insiders (NBIX) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2015-06-08 Coughlin Timothy P (Chief Financial Officer) Sale 60,000 45.08 2,704,800
2015-06-08 Coughlin Timothy P (Chief Financial Officer) Option Ex 60,000 2.59 155,400
2015-06-08 Obrien Christopher Flint (Chief Medical Officer) Sale 10,000 45.00 450,000
2015-06-08 Obrien Christopher Flint (Chief Medical Officer) Option Ex 10,000 5.76 57,600
2015-06-01 Gano Kyle (See Remarks) Sale 38,230 42.19 1,612,923
2015-06-01 Gano Kyle (See Remarks) Option Ex 38,230 4.17 159,610
2015-06-01 Obrien Christopher Flint (Chief Medical Officer) Sale 10,000 42.20 422,000
2015-06-01 Obrien Christopher Flint (Chief Medical Officer) Option Ex 10,000 5.76 57,600
2015-05-11 Pops Richard F (Director) Option Ex 15,000 4.76 71,400
2015-04-08 Nevinny Corinne H (Director) Option Ex 15,000 4.76 71,400
2015-04-07 Sherwin Stephen A (Director) Option Ex 15,000 4.76 71,400
2015-04-07 Neurocrine Biosciences Inc (Director) Option Ex 15,000 4.76 71,400
2015-03-24 Gorman Kevin Charles (President and CEO) Sale 40,000 41.53 1,661,200
2015-03-24 Gorman Kevin Charles (President and CEO) Option Ex 40,000 2.59 103,600
2015-03-24 Lyons Gary A (Director) Sale 30,000 41.53 1,245,900
2015-03-20 Coughlin Timothy P (Chief Financial Officer) Sale 40,000 44.49 1,779,600
2015-03-20 Coughlin Timothy P (Chief Financial Officer) Option Ex 40,000 2.59 103,600
2015-02-23 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 40.00 800,000
2015-02-23 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-02-10 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 35.00 700,000
2015-02-10 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-02-10 Lyons Gary A (Director) Option Ex 7,500 4.76 35,700
2015-01-20 Lyons Gary A (Director) Option Ex 7,500 4.76 35,700
2015-01-16 Gano Kyle (Chief Business Dev Officer) Sale 1,625 30.80 50,050
2015-01-16 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 30.77 50,001
2015-01-16 Bozigian Haig P. (Chief Development Officer) Sale 1,625 30.79 50,033
2015-01-16 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 30.81 53,917
2015-01-16 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 30.79 53,882
2015-01-16 Gorman Kevin Charles (President and CEO) Sale 3,750 30.79 115,462
2015-01-13 Gano Kyle (Chief Business Dev Officer) Sale 25,000 30.00 750,000
2015-01-13 Gano Kyle (Chief Business Dev Officer) Option Ex 25,000 4.17 104,375
2015-01-13 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 30.00 600,000
2015-01-13 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-01-13 Mitchell W Thomas (Director) Sale 45,000 30.07 1,353,150
2015-01-13 Mitchell W Thomas (Director) Option Ex 45,000 4.51 202,814
2015-01-12 Gano Kyle (Chief Business Dev Officer) Sale 1,250 28.41 35,512
2015-01-12 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 28.38 46,117
2015-01-12 Bozigian Haig P. (Chief Development Officer) Sale 1,625 28.45 46,231
2015-01-12 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 28.37 49,647
2015-01-12 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 28.41 49,717
2015-01-12 Gorman Kevin Charles (President and CEO) Sale 3,750 28.43 106,612
2015-01-08 Grigoriadis Dimitri E. (Chief Research Officer) Sale 30,000 27.39 821,700
2015-01-08 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 30,000 2.59 77,700
2015-01-08 Bozigian Haig P. (Chief Development Officer) Sale 30,000 27.30 819,150
2015-01-08 Bozigian Haig P. (Chief Development Officer) Option Ex 30,000 2.59 77,700
2015-01-08 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 27.25 272,500
2015-01-08 Coughlin Timothy P (Chief Financial Officer) Option Ex 10,000 2.59 25,900
2015-01-08 Obrien Christopher Flint (Chief Medical Officer) Sale 55,000 27.24 1,498,200
2015-01-08 Obrien Christopher Flint (Chief Medical Officer) Option Ex 55,000 2.59 142,450
2015-01-08 Gorman Kevin Charles (President and CEO) Sale 25,000 27.39 684,750
2015-01-08 Gorman Kevin Charles (President and CEO) Option Ex 25,000 2.59 64,750
2015-01-05 Grigoriadis Dimitri E. (Chief Research Officer) Sale 2,500 22.76 56,900
2015-01-05 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 2,500 5.12 12,800
2015-01-05 Bozigian Haig P. (Chief Development Officer) Sale 2,500 22.76 56,900
2015-01-05 Bozigian Haig P. (Chief Development Officer) Option Ex 2,500 5.12 12,800
2015-01-02 Mitchell W Thomas (Director) Sale 8,000 22.79 182,320
2015-01-02 Mitchell W Thomas (Director) Option Ex 8,000 4.76 38,080
2014-12-19 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 24.02 240,200
2014-12-19 Coughlin Timothy P (Chief Financial Officer) Option Ex 10,000 2.59 25,900
2014-12-19 Obrien Christopher Flint (CHIEF MEDICAL OFFICER) Sale 20,000 24.02 480,400
2014-12-19 Obrien Christopher Flint (CHIEF MEDICAL OFFICER) Option Ex 20,000 2.59 51,800
2014-12-19 Gorman Kevin Charles (PRESIDENT AND CEO) Sale 15,000 24.01 360,150
2014-12-18 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 23.18 463,600
2014-12-18 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 2.59 51,800
2014-12-18 Gorman Kevin Charles (PRESIDENT AND CEO) Sale 55,000 23.24 1,278,200
2014-12-18 Gorman Kevin Charles (PRESIDENT AND CEO) Option Ex 70,000 4.28 299,390
2014-12-17 Gano Kyle (Chief Business Dev Officer) Sale 4,957 22.50 111,532
2014-12-17 Gano Kyle (Chief Business Dev Officer) Option Ex 4,957 5.00 24,785
2014-12-17 Grigoriadis Dimitri E. (Chief Research Officer) Sale 14,706 22.50 330,885
2014-12-17 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 14,706 2.59 38,088
2014-12-17 Bozigian Haig P. (Chief Development Officer) Sale 15,002 22.51 337,695
2014-12-17 Bozigian Haig P. (Chief Development Officer) Option Ex 15,002 2.59 38,855
2014-12-15 Grigoriadis Dimitri E. (Chief Research Officer) Sale 2,500 21.71 54,275
2014-12-15 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 2,500 5.12 12,800
2014-12-15 Bozigian Haig P. (Chief Development Officer) Sale 2,500 21.72 54,300
2014-12-15 Bozigian Haig P. (Chief Development Officer) Option Ex 2,500 5.12 12,800
2014-12-12 Gano Kyle (Chief Business Dev Officer) Sale 4,043 22.50 90,967
2014-12-12 Gano Kyle (Chief Business Dev Officer) Option Ex 4,043 5.00 20,215
2014-12-12 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,294 22.50 231,615
2014-12-12 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 10,294 3.85 39,683
2014-12-12 Bozigian Haig P. (Chief Development Officer) Sale 9,998 22.50 224,955
2014-12-12 Bozigian Haig P. (Chief Development Officer) Option Ex 9,998 3.85 38,542
2014-12-12 Mollica Joseph A (Director) Option Ex 20,000 4.76 95,200
2014-12-11 Obrien Christopher Flint (Chief Medical Officer) Sale 19,875 22.10 439,237
2014-12-11 Obrien Christopher Flint (Chief Medical Officer) Option Ex 19,875 2.59 51,476
2014-12-10 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 21.48 429,500
2014-12-10 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 3.85 77,100
2014-12-10 Obrien Christopher Flint (Chief Medical Officer) Sale 20,125 21.77 438,221
2014-12-10 Obrien Christopher Flint (Chief Medical Officer) Option Ex 20,125 2.59 52,123
2014-12-10 Mitchell W Thomas (Director) Sale 7,000 21.90 153,300
2014-12-10 Mitchell W Thomas (Director) Option Ex 7,000 4.76 33,320
2014-11-28 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 20.14 201,400
2014-11-24 Obrien Christopher Flint (Chief Medical Officer) Sale 5,463 19.53 106,692
2014-11-17 Obrien Christopher Flint (Chief Medical Officer) Sale 11,300 19.51 220,463
2014-11-13 Obrien Christopher Flint (Chief Medical Officer) Sale 3,237 19.50 63,121
2014-11-10 Obrien Christopher Flint (Chief Medical Officer) Sale 20,000 18.62 372,400
2014-10-31 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 19.00 190,000
2014-10-30 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 18.62 186,200
2014-10-28 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 18.00 180,000
2014-10-01 Mitchell W Thomas (Director) Sale 1,275 15.50 19,762
2014-09-15 Lyons Gary A (Director) Sale 20,000 15.66 313,200
2014-05-12 Nevinny Corinne H (Director) Option Ex 12,000 12.37 148,440
2014-05-12 Pops Richard F (Director) Option Ex 12,000 12.37 148,440
2014-04-16 Mitchell W Thomas (Director) Option Ex 12,000 12.37 148,440
2014-04-16 Mollica Joseph A (Director) Option Ex 15,000 12.37 185,550
2014-04-16 Sherwin Stephen A (Director) Option Ex 12,000 12.37 148,440
2014-03-07 Lyons Gary A (Director) Option Ex 85,000 10.98 933,300
2014-01-17 Grigoriadis Dimitri E. (CHIEF RESEARCH OFFICER) Sale 25,000 20.00 500,000
2014-01-17 Grigoriadis Dimitri E. (CHIEF RESEARCH OFFICER) Option Ex 25,000 3.85 96,375
2014-01-17 Bozigian Haig P. (CHIEF DEVELOPMENT OFFICER) Sale 25,000 20.00 500,000
2014-01-17 Bozigian Haig P. (CHIEF DEVELOPMENT OFFICER) Option Ex 25,000 3.85 96,375
2014-01-10 Gano Kyle (Chief Business Dev Officer) Sale 1,250 18.57 23,212
2014-01-10 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 18.56 30,159
2014-01-10 Bozigian Haig P. (Chief Development Officer) Sale 1,625 18.58 30,192
2014-01-10 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 18.56 32,479
2014-01-10 Obrien Christopher Flint (Chief Medical Officer) Sale 6,750 18.77 126,731
2014-01-10 Gorman Kevin Charles (President and CEO) Sale 3,750 18.57 69,637
2014-01-07 Grigoriadis Dimitri E. (Chief Research Officer) Sale 25,000 17.50 437,500
2014-01-07 Bozigian Haig P. (Chief Development Officer) Sale 25,000 17.50 437,500
2014-01-07 Coughlin Timothy P (Chief Financial Officer) Sale 70,000 16.75 1,172,500
2014-01-07 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 17.50 87,500
2014-01-07 Gorman Kevin Charles (President and CEO) Sale 108,000 16.76 1,810,080
2013-09-04 Gano Kyle (Chief Business Dev Officer) Sale 2,400 15.61 37,464
2013-09-03 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 16.00 80,000
2013-08-21 Grigoriadis Dimitri E. (Chief Research Officer) Sale 13,600 15.04 204,612
2013-08-21 Bozigian Haig P. (Chief Development Officer) Sale 13,999 15.04 210,544
2013-08-21 Coughlin Timothy P (Chief Financial Officer) Sale 19,035 15.05 286,476
2013-08-06 Mitchell W Thomas (Director) Sale 1,531 14.70 22,505
2013-08-05 Grigoriadis Dimitri E. (Chief Research Officer) Sale 11,400 15.01 171,057
2013-08-05 Bozigian Haig P. (Chief Development Officer) Sale 11,001 15.00 165,015
2013-08-05 Coughlin Timothy P (Chief Financial Officer) Sale 10,965 14.99 164,365
2013-08-05 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 15.00 75,000
2013-07-12 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 14.50 72,500
2013-06-28 Obrien Christopher Flint (Chief Medical Officer) Sale 7,500 13.50 101,250
2013-06-27 Grigoriadis Dimitri E. (Chief Research Officer) Sale 3,837 13.00 49,881
2013-06-27 Bozigian Haig P. (Chief Development Officer) Sale 8,000 13.00 104,000
2013-06-27 Obrien Christopher Flint (Chief Medical Officer) Sale 3,857 13.00 50,141
2013-06-24 Bozigian Haig P. (Chief Development Officer) Sale 769 12.72 9,781
2013-06-21 Grigoriadis Dimitri E. (Chief Research Officer) Sale 25,937 12.80 331,915
2013-06-21 Bozigian Haig P. (Chief Development Officer) Sale 23,962 12.73 304,964
2013-06-21 Obrien Christopher Flint (Chief Medical Officer) Sale 14,926 12.70 189,515
2013-06-20 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,900 12.41 259,473
2013-06-20 Bozigian Haig P. (Chief Development Officer) Sale 20,769 12.43 258,054
2013-06-20 Obrien Christopher Flint (Chief Medical Officer) Sale 21,217 12.39 262,984
2013-03-28 Mitchell W Thomas (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Nevinny Corinne H (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Pops Richard F (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Mollica Joseph A (Director) Option Ex 15,000 10.60 159,000
2013-03-28 Sherwin Stephen A (Director) Option Ex 12,000 10.60 127,200
2012-12-05 Mitchell W Thomas (Director) Sale 900 7.41 6,669
 1   2   3 

Insider trading activities including stock purchases, stock sales, and option exercises of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX, CIK number 914475) see the Securities and Exchange Commission (SEC) website.